Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: May 14, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, press-release
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K with a press release on May 14th. Check for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 14, 2024, reporting for the month of May 2024. The filing includes Exhibit 99.1, a press release dated May 14, 2024. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release and does not appear to contain significant new financial or operational disclosures.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- May 14, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 001-41923 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to their security holders.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated May 14, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the SEC file number for Eupraxia Pharmaceuticals Inc.?
The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-05-14 07:04:02
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 15KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000604.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 14, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer